Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
Discovery Medicine|August 14, 2010
Rapid generation of high-level antibodies in vitro and in vivoJianmin Fang, Karin JoossClinical Immunology (Orlando, Fla.)|February 27, 2007
Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapyBetty Li, Melinda J VanRoey, Karin JoossInternational Reviews of Immunology|December 16, 2006
GM-CSF gene-modifed cancer cell immunotherapies: of mice and menKristen M Hege, Karin Jooss, Drew PardollExpert Opinion on Drug Safety|August 9, 2003
Safety of adeno-associated virus gene therapy vectors: a current evaluationPaul E Monahan, Karin Jooss, Mark S SandsClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapyBetty Li, Melinda VanRoey, Frederic Triebel, et al.European Journal of Immunology|September 11, 2002
Tolerance induction to self antigens by peripheral dendritic cellsFlorence Lambolez, Karin Jooss, Florence Vasseur, et al.Trends in Immunology|May 13, 2018
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be DifferentChung-Han Lee, Roman Yelensky, Karin Jooss, et al.Clinical Immunology (Orlando, Fla.)|July 2, 2013
Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapySpencer C Liang, Marina Moskalenko, Melinda Van Roey, et al.Clinical Immunology (Orlando, Fla.)|August 21, 2007
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAbBetty Li, Jianmin Lin, Melinda Vanroey, et al.Cancer Immunology, Immunotherapy : CII|January 13, 2006
The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administrationRodney A Prell, Lisa Gearin, Andrew Simmons, et al.Pageof 5